For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Tafamidis and the formulated version represents a true advancement . These novel therapies stabilize the transthyretin protein, preventing its destructive build-up and alleviating the burden of the illness. Individuals are now experienc